{
    "clinical_study": {
        "@rank": "156602", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to add DMP 266 to an\n      anti-HIV treatment program of indinavir and nucleoside reverse transcriptase inhibitors\n      (NRTIs)."
        }, 
        "brief_title": "A Study of Indinavir Taken With or Without DMP 266", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this double-blind, placebo-controlled study, 300 patients are randomized to 1 or 2\n      reverse transcriptase inhibitors of their choice plus blinded therapy on Arm A or B as\n      follows:\n\n      Arm A: DMP 266 placebo plus indinavir. Arm B: DMP 266 plus indinavir. After 16 weeks,\n      patients may switch the NRTI portion of their regimen if they meet a treatment failure\n      criterion. After the completion of the 24-week period, patients have the option to continue\n      on open-label DMP 266 and indinavir."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  CD4+ cell count of at least 50 cells/mm3.\n\n          -  HIV RNA level of at least 10,000 copies/ml by reverse transcriptase polymerase chain\n             reaction (RT-PCR, Amplicor test kit) at screening.\n\n          -  Signed, informed consent from parent or legal guardian for patients less than 18\n             years of age.\n\n        Exclusion Criteria\n\n        Prior Medication:\n\n        Excluded:\n\n          -  DMP 266.\n\n          -  Other nonnucleoside reverse transcriptase inhibitors.\n\n        Required:\n\n        One or two NRTIs (except ZDV and d4T in combination) for a minimum of 8 weeks, within 12\n        weeks prior to screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "300", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002393", 
            "org_study_id": "281A", 
            "secondary_id": "DMP 266-020"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Efavirenz", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Indinavir", 
                "Efavirenz", 
                "Reverse Transcriptase Inhibitors"
            ]
        }, 
        "keyword": [
            "Placebos", 
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "Indinavir", 
            "Reverse Transcriptase Inhibitors", 
            "efavirenz"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94118"
                    }, 
                    "name": "Kaiser Foundation Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30912"
                    }, 
                    "name": "Med College of Georgia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60610"
                    }, 
                    "name": "Chicago Ctr for Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "405360084"
                    }, 
                    "name": "Univ of Kentucky Med Ctr / Chandler Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70122"
                    }, 
                    "name": "Tulane Univ / Tulane / LSU Clinical Trials Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Mount Sinai Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ of Rochester Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "372321302"
                    }, 
                    "name": "Vanderbilt Univ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hampton", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23666"
                    }, 
                    "name": "Hampton Roads Med Specialists"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta"
                    }, 
                    "name": "Southern Alberta HIV Clinic / Foot Hills Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Ottawa Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00927"
                    }, 
                    "name": "Univ of Puerto Rico School of Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Puerto Rico"
            ]
        }, 
        "official_title": "A Phase III, Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir Versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "reference": {
            "PMID": "11133370", 
            "citation": "Haas DW, Fessel WJ, Delapenha RA, Kessler H, Seekins D, Kaplan M, Ruiz NM, Ploughman LM, Labriola DF, Manion DJ. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. J Infect Dis. 2001 Feb 1;183(3):392-400. Epub 2000 Dec 29."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002393"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dupont Merck", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1998"
    }, 
    "geocoordinates": {
        "Chicago Ctr for Clinical Research": "41.878 -87.63", 
        "Hampton Roads Med Specialists": "37.03 -76.345", 
        "Kaiser Foundation Hospital": "37.775 -122.419", 
        "Med College of Georgia": "33.474 -82.01", 
        "Mount Sinai Med Ctr": "40.714 -74.006", 
        "Ottawa Gen Hosp": "45.422 -75.697", 
        "Southern Alberta HIV Clinic / Foot Hills Hosp": "51.045 -114.057", 
        "Tulane Univ / Tulane / LSU Clinical Trials Unit": "29.951 -90.072", 
        "Univ of Kentucky Med Ctr / Chandler Med Ctr": "38.041 -84.504", 
        "Univ of Puerto Rico School of Medicine": "18.466 -66.106", 
        "Univ of Rochester Med Ctr": "43.161 -77.611", 
        "Vanderbilt Univ": "36.166 -86.784"
    }
}